UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 37

Sortiert nach

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

The lancet oncology, 2016-01, Vol.17 (1), p.27-38

2016

Link zum Volltext

Verfügbarkeit prüfen

Refractory anemia with ring sideroblasts masked by iron deficiency anemia

Blood, 2011-06, Vol.117 (22), p.5793-5793

2011

Link zum Volltext

Verfügbarkeit prüfen

Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study

Leukemia & lymphoma, 2012-01, Vol.53 (1), p.57-63

2012

Link zum Volltext

Verfügbarkeit prüfen

The pandemic H1N1 influenza vaccine results in low rates of seroconversion for patients with hematological malignancies

Leukemia & lymphoma, 2011-09, Vol.52 (9), p.1736-1741

2011

Link zum Volltext

Verfügbarkeit prüfen

Attitudes toward vaccination for pandemic H1N1 and seasonal influenza in patients with hematologic malignancies

The Journal of supportive oncology, 2011-07, Vol.9 (4), p.156

2011

Link zum Volltext

Verfügbarkeit prüfen

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

The lancet oncology, 2017-10, Vol.18 (10), p.1327-1337

2017

Link zum Volltext

Verfügbarkeit prüfen

Real-World Treatment Outcomes and Toxicities of Outpatient R-CHOP/R-DHAP in Patients with Mantle Cell Lymphoma Eligible for Autologous Stem Cell Transplant

Blood, 2022-11, Vol.140 (Supplement 1), p.11983-11984

2022

Link zum Volltext

Verfügbarkeit prüfen

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

The New England journal of medicine, 2016-10, Vol.375 (14), p.1319-1331

2016

Link zum Volltext

Verfügbarkeit prüfen

Effect of unintentional cyclophosphamide underdosing on diffuse large B-cell lymphoma response to chemotherapy: a retrospective review

CMAJ open, 2016-05, Vol.4 (2), p.E236-E239

2016

Link zum Volltext

Verfügbarkeit prüfen

Decreased hepatocyte membrane potential differences and GABAa‐β3 expression in human hepatocellular carcinoma

Hepatology (Baltimore, Md.), 2007-03, Vol.45 (3), p.735-745

2007

Link zum Volltext

Verfügbarkeit prüfen

Normal levels of protein C and protein S tested in the acute phase of a venous thromboembolic event are not falsely elevated

Thrombosis journal, 2010-05, Vol.8 (1), p.10-10

2010

Link zum Volltext

Verfügbarkeit prüfen

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.6540-6542

2022

Link zum Volltext

Verfügbarkeit prüfen

Favezelimab (anti–LAG-3) plus pembrolizumab in patients with anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7516-7516

2022

Link zum Volltext

Verfügbarkeit prüfen

Monoclonal Protein Response Trajectory and Survival in Newly Diagnosed Multiple Myeloma: A Retrospective Cohort Study

Blood, 2020-11, Vol.136 (Supplement 1), p.24-24

2020

Link zum Volltext

Verfügbarkeit prüfen

Spontaneous Retroperitoneal Hemorrhage in a Patient with Prolymphocytic Transformation of Chronic Lymphocytic Leukemia

Case reports in hematology, 2013-01, Vol.2013, p.802376-3

2013

Link zum Volltext

Verfügbarkeit prüfen

Desmopressin responsiveness at a capped dose of 15 μg in type 1 von Willebrand disease and mild hemophilia A

Blood coagulation & fibrinolysis, 2014-12, Vol.25 (8), p.820-823

2014

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Mini-CHOP-R Chemotherapy for Treatment of Diffuse Large B Cell Lymphoma in Very Elderly Patients: A Quality Assurance Study

Blood, 2015-12, Vol.126 (23), p.2720-2720

2015

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Proteasome Inhibition Activity between Carfilzomib and Bortezomib in the Phase 3 Endeavor Study

Blood, 2017-12, Vol.130, p.3125-3125

2017

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Dose Attentuated R-CHOP Chemotherapy for Treatment of Diffuse Large B Cell Lymphoma in the Very Elderly: A Cohort Study

Blood, 2014-12, Vol.124 (21), p.5447-5447

2014

Link zum Volltext

Verfügbarkeit prüfen

Effect of Unintentional Cyclophosphamide Under-Dosing on Disease Response and Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Blood, 2014-12, Vol.124 (21), p.5441-5441

2014

Link zum Volltext

Verfügbarkeit prüfen

A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting

Journal of oncology pharmacy practice, 2021-06, Vol.27 (4), p.907-910

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(37)

Sprache

Englisch
(37)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(12)
Science & Technology
(12)
Humans
(10)
Aged
(8)
Female
(8)
Male
(8)
Hematology
(7)
Middle Aged
(7)
Oncology
(6)
Adult
(5)
Aged, 80 And Over
(5)
Multiple Myeloma
(5)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(4)
Dexamethasone
(4)
Dexamethasone - Administration & Dosage
(4)
Multiple Myeloma - Drug Therapy
(4)
Adolescent
(3)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)
Disease-Free Survival
(3)
Health Risk Assessment
(3)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(30)
Publisher website
(20)
Ovid Journals
(9)
Ingenta
(8)
IngentaConnect Journals
(3)
Elsevier ScienceDirect Journals Complete
(3)
SpringerLink
(3)
Wiley Online Library Journals
(2)
Taylor & Francis Online
(2)
Wiley Online Library
(2)
Taylor & Francis
(2)
Sage Journals
(1)

7 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

P1065: UPDATED RESULTS FROM AN OPEN‐LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD‐1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

P061: Safety and Dose‐Expansion Study of Combination Favezelimab (anti–LAG‐3) Plus Pembrolizumab in Anti–PD‐1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Refractory anemia with ring sideroblasts masked by iron deficiency anemia

Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study

The pandemic H1N1 influenza vaccine results in low rates of seroconversion for patients with hematological malignancies

Attitudes toward vaccination for pandemic H1N1 and seasonal influenza in patients with hematologic malignancies

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

Real-World Treatment Outcomes and Toxicities of Outpatient R-CHOP/R-DHAP in Patients with Mantle Cell Lymphoma Eligible for Autologous Stem Cell Transplant

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Effect of unintentional cyclophosphamide underdosing on diffuse large B-cell lymphoma response to chemotherapy: a retrospective review

Decreased hepatocyte membrane potential differences and GABAa‐β3 expression in human hepatocellular carcinoma

Normal levels of protein C and protein S tested in the acute phase of a venous thromboembolic event are not falsely elevated

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

Favezelimab (anti–LAG-3) plus pembrolizumab in patients with anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study

Monoclonal Protein Response Trajectory and Survival in Newly Diagnosed Multiple Myeloma: A Retrospective Cohort Study

Spontaneous Retroperitoneal Hemorrhage in a Patient with Prolymphocytic Transformation of Chronic Lymphocytic Leukemia

Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide

Desmopressin responsiveness at a capped dose of 15 μg in type 1 von Willebrand disease and mild hemophilia A

Safety and Efficacy of Mini-CHOP-R Chemotherapy for Treatment of Diffuse Large B Cell Lymphoma in Very Elderly Patients: A Quality Assurance Study

Comparison of Proteasome Inhibition Activity between Carfilzomib and Bortezomib in the Phase 3 Endeavor Study

Safety and Efficacy of Dose Attentuated R-CHOP Chemotherapy for Treatment of Diffuse Large B Cell Lymphoma in the Very Elderly: A Cohort Study

Effect of Unintentional Cyclophosphamide Under-Dosing on Disease Response and Outcomes in Patients with Diffuse Large B-Cell Lymphoma

A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting

Suchergebnisse filtern